• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DLL3表达和甲基化与低级别胶质瘤的免疫微环境及预后相关。

DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.

作者信息

Noor Humaira, Whittaker Shane, McDonald Kerrie L

机构信息

Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales 2031, Australia; Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Randwick, NSW 2031, Australia.

Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales 2031, Australia; Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Randwick, NSW 2031, Australia; Platelet, Thrombosis and Cancer Research Lab, ANZAC Research Institute, New South Wales 2031, Australia.

出版信息

Genomics. 2022 Mar;114(2):110289. doi: 10.1016/j.ygeno.2022.110289. Epub 2022 Feb 4.

DOI:10.1016/j.ygeno.2022.110289
PMID:35124175
Abstract

Notch signalling pathway, particularly its ligand delta-ligand 3 (DLL3), is important in glioma, however, little is known about DLL3 regulation and prognostic effects. Immunohistochemistry on a cohort of 163 gliomas revealed DLL3 upregulation in IDH1 mutant gliomas, where it was associated with a favourable prognosis (HR[95% CI]: 0.28[0.09-0.87]; p = 0.021). We investigated the epigenetic regulation of DLL3, and identified individual CpG sites correlating with DLL3 mRNA expression, which were significant prognostic markers in LGG. In silico analysis revealed that infiltrating immune cells significantly correlated with DLL3 expression, methylation and somatic copy number alterations. The prognostic effects of DLL3 expression was significantly affected by infiltration of immune cells. RNA Sequencing of 83 LGGs and GO Term analysis of differentially expressed genes showed that low DLL3 expression was related to ciliogenesis, which was confirmed by TCGA LGG analysis. Thus, DLL3 may play an important role in the immune microenvironment and prognosis of LGGs.

摘要

Notch信号通路,尤其是其配体δ-配体3(DLL3),在胶质瘤中很重要,然而,关于DLL3的调控和预后影响知之甚少。对163例胶质瘤队列进行的免疫组织化学分析显示,DLL3在异柠檬酸脱氢酶1(IDH1)突变型胶质瘤中上调,且与良好预后相关(风险比[95%置信区间]:0.28[0.09 - 0.87];p = 0.021)。我们研究了DLL3的表观遗传调控,并确定了与DLL3 mRNA表达相关的单个CpG位点,这些位点是低级别胶质瘤(LGG)中的显著预后标志物。计算机分析显示,浸润性免疫细胞与DLL3表达、甲基化和体细胞拷贝数改变显著相关。免疫细胞浸润显著影响DLL3表达的预后作用。对83例LGG进行的RNA测序和差异表达基因的基因本体(GO)术语分析表明,低DLL3表达与纤毛发生有关,这在癌症基因组图谱(TCGA)的LGG分析中得到了证实。因此,DLL3可能在LGG的免疫微环境和预后中发挥重要作用。

相似文献

1
DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.DLL3表达和甲基化与低级别胶质瘤的免疫微环境及预后相关。
Genomics. 2022 Mar;114(2):110289. doi: 10.1016/j.ygeno.2022.110289. Epub 2022 Feb 4.
2
Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma.整合基因表达与甲基化分析确定DLL3为恶性胶质瘤预后的生物标志物。
J Mol Neurosci. 2021 Aug;71(8):1622-1635. doi: 10.1007/s12031-021-01817-7. Epub 2021 Mar 13.
3
[Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].[多分级胶质瘤异质性和免疫微环境的单细胞转录组分析揭示潜在预后生物标志物]
Sheng Wu Gong Cheng Xue Bao. 2022 Oct 25;38(10):3790-3808. doi: 10.13345/j.cjb.220481.
4
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.细胞表面 Notch 配体 DLL3 是异柠檬酸脱氢酶突变型脑胶质瘤的治疗靶点。
Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.
5
SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.SYT16 是胶质母细胞瘤的预后生物标志物,并与免疫浸润相关:基于 TCGA 数据的研究。
Int Immunopharmacol. 2020 Jul;84:106490. doi: 10.1016/j.intimp.2020.106490. Epub 2020 Apr 11.
6
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.CKS2(CDC28 蛋白激酶调节亚基 2)是低级别胶质瘤的预后生物标志物:基于生物信息学分析和免疫组织化学的研究。
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.
7
Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.丝氨酸掺入因子 2(SERINC2)表达预测低级别胶质瘤(LGG)的不良预后:来自生物信息学分析的证据。
J Mol Neurosci. 2020 Oct;70(10):1521-1532. doi: 10.1007/s12031-020-01620-w. Epub 2020 Jul 8.
8
Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.神经调节蛋白家族成员相关肿瘤微环境的综合分析预测胶质瘤的预后。
Front Immunol. 2021 May 13;12:682415. doi: 10.3389/fimmu.2021.682415. eCollection 2021.
9
An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.预测低级别胶质瘤预后的免疫相关标志物。
Front Immunol. 2020 Dec 8;11:603341. doi: 10.3389/fimmu.2020.603341. eCollection 2020.
10
Expression of delta-like 3 is downregulated by aberrant DNA methylation and histone modification in hepatocellular carcinoma.在肝癌中,delta-like 3 的表达受异常的 DNA 甲基化和组蛋白修饰下调。
Oncol Rep. 2018 May;39(5):2209-2216. doi: 10.3892/or.2018.6293. Epub 2018 Mar 5.

引用本文的文献

1
Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review.胶质瘤中的表观遗传重编程与抗肿瘤免疫反应:一项系统综述
Med Oncol. 2025 May 16;42(6):213. doi: 10.1007/s12032-025-02760-y.
2
Targeting DLL3: Innovative Strategies for Tumor Treatment.靶向DLL3:肿瘤治疗的创新策略。
Pharmaceutics. 2025 Apr 16;17(4):520. doi: 10.3390/pharmaceutics17040520.
3
Robust Cluster Prediction Across Data Types Validates Association of Sex and Therapy Response in GBM.跨数据类型的稳健聚类预测验证了胶质母细胞瘤中性别与治疗反应的关联。
Cancers (Basel). 2025 Jan 28;17(3):445. doi: 10.3390/cancers17030445.
4
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Notch 信号通路与癌症:从机制研究到靶向治疗。
Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x.
5
The Role of Antibody-Based Therapies in Neuro-Oncology.基于抗体的疗法在神经肿瘤学中的作用。
Antibodies (Basel). 2023 Nov 13;12(4):74. doi: 10.3390/antib12040074.
6
Impact of epigenetic reprogramming on antitumor immune responses in glioma.表观遗传重编程对胶质瘤抗肿瘤免疫反应的影响。
J Clin Invest. 2023 Jan 17;133(2):e163450. doi: 10.1172/JCI163450.
7
Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance.胶质瘤中Notch信号通路异常:治疗耐药联合治疗中潜在的可操作汇聚靶点格局
Cancer Drug Resist. 2022 Oct 18;5(4):939-953. doi: 10.20517/cdr.2022.46. eCollection 2022.